Vivo Capital, LLC Gracell Biotechnologies Inc. Transaction History

Vivo Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	SELL	$2.43 - $10.04 $3.24 Million - $13.4 Million	-1,334,659 Reduced 12.27%	9,546,485 $95.8 Million
Q3 2023 Nov 08, 2023	BUY	$2.83 - $4.9 $19.6 Million - $33.9 Million	6,911,717 Added 174.12%	10,881,144 $31.3 Million
Q2 2023 Aug 14, 2023	BUY	$1.45 - $6.07 $3.63 Million - $15.2 Million	2,505,444 Added 171.14%	3,969,427 $15.1 Million
Q1 2023 May 12, 2023	BUY	$1.8 - $2.5 $904,725 - $1.26 Million	502,625 Added 52.28%	1,463,983 $2.72 Million
Q4 2022 Feb 13, 2023	SELL	$2.08 - $3.96 $2 - $3	-1 Reduced -0.0%	961,358 $2.21 Million
Q3 2021 Nov 15, 2021	SELL	$9.91 - $14.84 $3.64 Million - $5.44 Million	-366,898 Reduced 27.62%	961,359 $13.3 Million
Q2 2021 Aug 16, 2021	SELL	$9.75 - $18.42 $1.9 Million - $3.59 Million	-194,737 Reduced 12.79%	1,328,257 $17.3 Million
Q1 2021 May 17, 2021	BUY	$14.7 - $30.57 $22.4 Million - $46.6 Million	1,522,994 New	1,522,994 $23.5 Million

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of Vivo Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Vivo Capital, LLC with notifications on news.